Yuekang Pharmaceutical: YKYY017 aerosol inhaler obtains clinical trial approval for new indications.

Yuekang Pharmaceutical announced that the company recently obtained the "Drug Clinical Trial Approval Notification" issued by the NMPA, which approves the clinical trial of YKYY017 aerosol inhalation for the treatment and prevention of respiratory infections associated with human coronavirus OC43. This product has previously received clinical approvals in China, the United States, and Australia for the prevention and treatment of novel coronavirus infections. The addition of this indication marks the expansion of the pipeline from a single virus to a significant respiratory virus spectrum.